Victoza Indications/Uses



Novo Nordisk


Zuellig Pharma
Full Prescribing Info
Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control: In combination with: Metformin or a sulfonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin or sulphonylurea.
In combination with: Metformin and a sulfonylurea or metformin and a thiazolidinedione in patients with insufficient glycaemic control despite dual therapy.
Combination therapy with metformin and insulin in patients not achieving adequate glycaemic control with Victoza and metformin.
Prevention of cardiovascular events: Victoza is indicated to reduce the risk of major adverse cardiovascular events (MACE), composed of cardiovascular (CV) death, non-fatal myocardial infarction and non-fatal stroke, in adults with type 2 diabetes who have established CV disease or are at high risk for CV disease.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in